Calithera Biosciences Inc. (NASDAQ:CALA) saw an uptick in trading volume on Tuesday . 147,060 shares changed hands during mid-day trading, an increase of 25% from the previous session’s volume of 117,883 shares.The stock last traded at $3.19 and had previously closed at $3.07.
Separately, JMP Securities restated a “buy” rating on shares of Calithera Biosciences in a research note on Wednesday, June 8th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $10.38.
The company’s market capitalization is $61.78 million. The stock has a 50 day moving average of $3.15 and a 200 day moving average of $4.42.
Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.03. Equities research analysts expect that Calithera Biosciences Inc. will post ($2.16) earnings per share for the current year.
Large investors have recently modified their holdings of the company. Jacobs Levy Equity Management Inc. acquired a new stake in Calithera Biosciences during the first quarter worth about $218,000. Paloma Partners Management Co acquired a new stake in Calithera Biosciences during the second quarter worth about $150,000. GSA Capital Partners LLP raised its stake in Calithera Biosciences by 25.9% in the second quarter. GSA Capital Partners LLP now owns 43,800 shares of the company’s stock worth $162,000 after buying an additional 9,000 shares during the last quarter. Geode Capital Management LLC raised its stake in Calithera Biosciences by 6.9% in the first quarter. Geode Capital Management LLC now owns 66,250 shares of the company’s stock worth $376,000 after buying an additional 4,286 shares during the last quarter. Finally, State Street Corp raised its stake in Calithera Biosciences by 18.7% in the first quarter. State Street Corp now owns 111,052 shares of the company’s stock worth $632,000 after buying an additional 17,496 shares during the last quarter. 48.26% of the stock is owned by institutional investors.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.